Keyphrases
Tumor Progression
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Tumor Therapy
100%
Ligand Interaction
100%
Multiple Ligands
100%
Proteolysis
25%
Clinical Trials
12%
Cancer Treatment
12%
Angiogenesis
12%
Metastasis
12%
Plasminogen Activator inhibitor-1 (PAI-1)
12%
Cell Signaling
12%
Cell Proliferation
12%
Cell Surface
12%
Malignancy
12%
Specific Inhibitor
12%
Serine Protease
12%
Cell Survival
12%
Receptor-targeted Therapy
12%
Cancer Targeting
12%
Surface Systems
12%
Plasminogen Activator inhibitor-2
12%
Extracellular Proteolysis
12%
Medicine and Dentistry
Tumor Progression
100%
Cancer Therapy
100%
Urokinase Receptor
100%
Protein Degradation
37%
Receptor
12%
Angiogenesis
12%
Metastatic Carcinoma
12%
Cell Surface
12%
Malignant Neoplasm
12%
Serine Proteinase
12%
Plasminogen Activator Inhibitor-2
12%
Clinical Trial
12%
Cancer
12%
Targeted Therapy
12%
Cancer Treatment
12%
Signal Transduction
12%
Plasminogen Activator Inhibitor-1
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Growth
100%
Urokinase Receptor
100%
Malignant Neoplasm
25%
Clinical Trial
12%
Receptor
12%
Plasminogen Activator Inhibitor 1
12%
Serine Proteinase
12%
Plasminogen Activator Inhibitor 2
12%
Neuroscience
Urokinase Receptor
100%
Proteolysis
37%
Cell Signaling
12%
Serine Protease
12%
Plasminogen Activator Inhibitor-2
12%
Angiogenesis
12%
Receptor
12%
Plasminogen Activator Inhibitor-1
12%